A Phase 2 Trial Investigating Epcoritamab in Patients with Previously Treated Waldenstrom Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (WM-NET3)

被引：1
|
作者：
von Keudell, Gottfried [1 ,2 ]
Logan, Emma K. [2 ]
Redd, Robert A. [3 ]
Sarosiek, Shayna R. [4 ,5 ]
Branagan, Andrew R. [6 ]
Anderson Jr, Larry D. [7 ]
Dittus, Christopher [8 ]
Treon, Steven P. [5 ]
Castillo, Jorge J. [4 ,9 ]
机构：
[1] Harvard Med Sch, Boston, MA USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA
[4] Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, Boston, MA USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Massachusetts Gen Hosp Canc Ctr, Ctr Multiple Myeloma, Boston, MA USA
[7] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[8] Univ North Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[9] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-206415
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6294 / 6295
页数：2
相关论文
共 50 条
  • [41] A phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated waldenstrom's macroglobulinemia (WM).
    Rossi, Jean-Francois
    Moreaux, Jerome
    Rose, Mikaelle
    Picard, Marie
    Ythier, Arnaud
    Rossier, Ciara
    Sievers, Eric
    Klein, Bernard
    BLOOD, 2006, 108 (11) : 1022A - 1022A
  • [42] Three-year follow-up of treatment-naive and previously treated patients with Waldenstrom macroglobulinemia (WM) receiving single-agent zanubrutinib.
    Tam, Constantine Si Lun
    Opat, Stephen
    Marlton, Paula
    Gottlieb, David
    Simpson, David
    Cull, Gavin
    Ritchie, David
    Verner, Emma
    Munoz, Javier
    Tedeschi, Alessandra
    Huang, Jane
    Novotny, William
    Tan, Ziwen
    Holmgren, Eric
    Atwal, Siminder K.
    Seymour, John Francis
    Roberts, Andrew Warwick
    Trotman, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenstrom macroglobulinemia (WM).
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM)
    Yukio Kobayashi
    International Journal of Hematology, 2019, 110 : 524 - 528
  • [45] Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom's Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party
    Kyriakou, Charalampia
    Boumendil, Ariane
    Finel, Herve
    Vernant, Jean-Paul
    Cornelissen, Jan J.
    Thieblemont, Catherine
    Chevallier, Patrice
    Hamladji, Rose-Marie
    Mufti, Ghulam J.
    Mazza, Patrizio
    Zachee, Pierre
    Niederwieser, Dietger
    Sureda, Anna
    Montoto, Silvia
    Dreger, Peter
    BLOOD, 2014, 124 (21)
  • [46] 2-chlorodeoxyadenosine (2-CdA) and cyclophosphamide (Cy) alone or in combination with Rituximab (Rit) for previously untreated Waldenstrom's Macroglobulinemia (WM).
    Weber, DM
    Wang, M
    Delasalle, KB
    Gavino, M
    Alexaman, R
    BLOOD, 2004, 104 (11) : 413A - 413A
  • [47] Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia (LPL/WM) in bone marrow: Pax-5 immunostain highlights a vascular-centered tumor growth with variations in cellular composition and architecture in lymphoplasmacytoid, lymphoplasmacytic and polymorphous subtypes
    Wahed, A
    Medeircs, LJ
    Mansoor, A
    Bueso-Ramos, CE
    LABORATORY INVESTIGATION, 2003, 83 (01) : 257A - 257A
  • [48] Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, (LPL/WM) in bone marrow: Pax-5 immunostain highlights a vascular-centered tumor growth with variations in cellular composition and architecture in lymphoplasmacytoid, lymphoplasmacytic and polymorphous subtypes
    Wahed, A
    Medeiros, LJ
    Mansoor, A
    Bueso-Ramos, CE
    MODERN PATHOLOGY, 2003, 16 (01) : 257A - 257A
  • [49] Fludarabine therapy in Waldenstrom's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine
    Lewandowski, K
    Halaburda, K
    Hellmann, A
    LEUKEMIA & LYMPHOMA, 2002, 43 (02) : 361 - 363
  • [50] Rituximab, cyclophosphamide, dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient
    Mohammad, RM
    Aboukameel, A
    Nabha, S
    Ibrahim, D
    Al-Katib, A
    JOURNAL OF DRUG TARGETING, 2002, 10 (05) : 405 - 410
12345